| Targeting the PD-1/PD-L1 axis for the treatment of non-small-cell lung cancer DE Meyers, PM Bryan, S Banerji, DG Morris Current oncology 25 (4), 324-334, 2018 | 70 | 2018 |
| Oncolytic reovirus and immune checkpoint inhibition as a novel immunotherapeutic strategy for breast cancer AA Mostafa, DE Meyers, CM Thirukkumaran, PJ Liu, K Gratton, J Spurrell, ... Cancers 10 (6), 205, 2018 | 61 | 2018 |
| The lung immune prognostic index discriminates survival outcomes in patients with solid tumors treated with immune checkpoint inhibitors DE Meyers, I Stukalin, IA Vallerand, RT Lewinson, A Suo, M Dean, ... Cancers 11 (11), 1713, 2019 | 59 | 2019 |
| Evaluation of the clinical benefit of cancer drugs submitted for reimbursement recommendation decisions in Canada DE Meyers, K Jenei, TM Chisamore, B Gyawali JAMA Internal Medicine 181 (4), 499-508, 2021 | 33 | 2021 |
| Aplastic anemia secondary to nivolumab and ipilimumab in a patient with metastatic melanoma: a case report DE Meyers, WF Hill, A Suo, V Jimenez-Zepeda, T Cheng, NA Nixon Experimental Hematology & Oncology 7, 1-6, 2018 | 29 | 2018 |
| Current immunotherapeutic strategies to enhance oncolytic virotherapy DE Meyers, AA Wang, CM Thirukkumaran, DG Morris Frontiers in Oncology 7, 114, 2017 | 29 | 2017 |
| Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials CL Gan, I Stukalin, DE Meyers, S Dudani, HAI Grosjean, S Dolter, ... European Journal of Cancer 151, 115-125, 2021 | 28 | 2021 |
| Trends in drug revenue among major pharmaceutical companies: A 2010‐2019 cohort study DE Meyers, BS Meyers, TM Chisamore, K Wright, B Gyawali, V Prasad, ... Cancer 128 (2), 311-316, 2022 | 26 | 2022 |
| Biomarkers of immune checkpoint inhibitor efficacy in cancer DE Meyers, S Banerji Current Oncology 27 (s2), 106-114, 2020 | 25 | 2020 |
| Oncolytic virotherapy as an immunotherapeutic strategy for multiple myeloma DE Meyers, S Thakur, CM Thirukkumaran, DG Morris Blood Cancer Journal 7 (12), 640, 2017 | 22 | 2017 |
| Industry relationships with medical oncologists: who are the high-payment physicians? K Wright, DE Meyers, TM Chisamore, MDF McInnes, S Sismondo, ... JCO Oncology Practice 18 (7), e1164-e1169, 2022 | 20 | 2022 |
| Association of immune-related adverse events, hospitalization, and therapy resumption with survival among patients with metastatic melanoma receiving single-agent or … AS Watson, S Goutam, I Stukalin, BW Ewanchuk, M Sander, DE Meyers, ... JAMA Network Open 5 (12), e2245596-e2245596, 2022 | 19 | 2022 |
| Effectiveness and safety of first-line pembrolizumab in older adults with PD-L1 positive non-small cell lung cancer: a retrospective cohort study of the Alberta immunotherapy … HAI Grosjean, S Dolter, DE Meyers, PQ Ding, I Stukalin, S Goutam, ... Current Oncology 28 (5), 4213-4222, 2021 | 19 | 2021 |
| Second‐line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real‐world eligibility for cabozantinib … AS Fung, VC Tam, DE Meyers, HW Sim, JJ Knox, V Zaborska, J Davies, ... Cancer Medicine 9 (13), 4640-4647, 2020 | 18 | 2020 |
| The inclusion of women in global oncology drug trials over the past 20 years K Jenei, DE Meyers, V Prasad JAMA oncology 7 (10), 1569-1570, 2021 | 17 | 2021 |
| Oncology education for family medicine residents: a national needs assessment survey SM Yip, DE Meyers, J Sisler, K Wycliffe-Jones, E Kucharski, C Elser, ... BMC Medical Education 20, 1-9, 2020 | 16 | 2020 |
| Real world eligibility for cabozantinib (C), regorafenib (Reg), and ramucirumab (Ram) in hepatocellular carcinoma (HCC) patients after sorafenib (S). AS Fung, VC Tam, DE Meyers, HW Sim, JJ Knox, VO Zaborska, ... Journal of Clinical Oncology 37 (4_suppl), 422-422, 2019 | 10 | 2019 |
| Machine learning for prediction of cutaneous adverse events in patients receiving anti–PD-1 immunotherapy RT Lewinson, DE Meyers, IA Vallerand, A Suo, ML Dean, T Cheng, ... Journal of the American Academy of Dermatology 84 (1), 183-185, 2021 | 9 | 2021 |
| Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors S Cook, V Samuel, DE Meyers, I Stukalin, I Litt, R Sangha, DG Morris, ... JAMA Network Open 7 (1), e2352302-e2352302, 2024 | 8 | 2024 |
| The role of immunotherapy in the treatment of malignant pleural mesothelioma S Banerji, DE Meyers, C Harlos, DE Dawe Current Oncology 28 (6), 4542-4551, 2021 | 7 | 2021 |
